Last week, the Institute for Gene Therapies (IGT) sent a response to the Health Resources and Services Administration (HRSA) Request for...

As we recognize National Minority Health Month (NMHM), the Institute for Gene Therapies (IGT)’s Scientific, Academic and Medical Advisory...

On February 14, IGT Chairman Erik Paulsen joined a panel of experts at the American Enterprise Institute’s (AEI) event, “Navigating...

This week, the Institute for Gene Therapies (IGT) sent a response to the Senate Health, Education, Labor, and Pensions (HELP) Committee...

On December 13, the Institute for Gene Therapies held its third Congressional Briefing of 2023, "Realizing the Promise of Gene Therapy:...

Gene therapies are changing the way we treat diseases by targeting the cause of a disease directly at the DNA level, rather than...

By IGT Director of Health Policy & Advocacy John Feore This month, I had the opportunity to participate in the American Society of Cell...

On June 26th, the Institute for Gene Therapies hosted its second Congressional Briefing focused on the promise of gene therapy, its...

Lauren Holder, Huntington’s Disease Patient Advocate and member of the Institute for Gene Therapy Patient Advocacy Advisory Council,...

Patients, researchers, and other key stakeholders are weighing in on the importance of the Medicaid VBPs for Patients Act, or the MVP Act...